Lung Cancer

The Food and Drug Administration (FDA) granted priority review to Keytruda (pembrolizumab) monotherapy for the first-line treatment of patients with locally advanced or metastatic nonsquamous or squamous non-small cell lung cancer (NSCLC) whose tumors express PD-L1 without EGFR or ALK genomic tumor aberrations.

A small study showed that, despite national guideline recommendation, conversations between doctors and patients about the benefits and harms of lung cancer screening in those who are at high risk are not happening the way they should be.

After success in the non-small cell lung cancer space, immunotherapy is finally making waves in the treatment of small cell lung cancer.

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.

The researchers found that the trial that led to the guidelines – which recommend screening based on age and smoking history – did not include fair representation from all groups across the nation.

Broad-based genomic sequencing, while useful in identifying tumor mutations in patients with non-small cell lung cancer (NSCLC), may not improve survival outcomes when compared to routine genomic testing.

The Food and Drug Administration (FDA) has granted a full approval to frontline Keytruda (pembrolizumab) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), based on findings from the phase 3 KEYNOTE-189 trial.

This is the first approval in the small cell lung cancer space in nearly two decades.

Caring for a young person with cancer can be a challenge, explains Nancy Bell.

In a global analysis, researchers found global lung cancer mortality rates are projected to increase by 43 percent in women; however, breast cancer rates should decline by 9 percent.

Clinical trials are starting to focus more on the tumor's genetic makeup than the tumor's location.

Scientists have spent 35 years seeking ways to disable RAS, a gene that’s mutated in many cancer types. Now, they’re moving closer to solutions.

When first diagnosed with lung cancer, some doctors told Bonnie J. Addario that there was nothing that they could do for her. Now, 14 years later, she has spent over a decade helping others with the disease through her Bonnie J. Addario Lung Cancer Foundation.

A newly developed blood test may identify people at an increased risk for lung cancer, even if they are not within the screening guidelines.

"Scanxiety" is common in people with cancer, but is particularly prevalent in those with lung cancer, according to a recent survey.

Investigators at The University of Texas MD Anderson Cancer Center in Houston discovered that adding the PARP inhibitor veliparib to a standard chemotherapy regimen improved overall responses rates (ORR) in patients with relapsed small cell lung cancer (SCLC).

The majority of adolescent and young adult (AYA) patients who are diagnosed with cancer are expected to live past the five-year mark, though survival and health outcomes seem to differ by disease type, according to recent research published in the journal Cancer.